---
aliases: [Isomorphic]
---
#actor #biotech #ai #drugdiscovery #uk #private

**Isomorphic Labs** — Alphabet/DeepMind spinout. AlphaFold 3 platform. $3B [[Novartis]] + Lilly deals. $600M raised.

---

## Why Isomorphic matters

| Metric | Value |
|--------|-------|
| Parent | Alphabet (DeepMind spinout) |
| Founded | 2021 |
| Funding | **$600M** (Mar 2025) |
| Pharma deals | **~$3B** ([[Novartis]] + Lilly) |
| Technology | AlphaFold 3 |

---

## AlphaFold 3 platform

| Capability | Description |
|------------|-------------|
| Protein structure | 3D folding prediction |
| Molecular interactions | Protein-DNA-RNA-ligand modeling |
| Drug design | Structure-based optimization |
| Speed | Days vs months |

**Evolution:** AlphaFold 1 (2018) → AlphaFold 2 (2020, breakthrough) → AlphaFold 3 (2024, interactions).

---

## Pharma partnerships

### Eli Lilly

| Metric | Value |
|--------|-------|
| Upfront | $45M |
| Milestones | Up to $1.7B |
| Targets | Multiple, undisclosed |
| Focus | Small molecules |

### [[Novartis]]

| Metric | Value |
|--------|-------|
| Upfront | $37.5M |
| Research funding | Additional |
| Milestones | Up to $1.2B |
| Targets | 3 undisclosed |
| Focus | Small molecules |

**Combined value:** ~$3B in potential payments.

---

## Clinical progress

| Status | Detail |
|--------|--------|
| Trials planned | Oncology candidates |
| Timeline | First patients 2026 |
| Strategy | Internal + partnered |

**CEO Colin Murdoch (2025):** Preparing to dose first patients in clinical trials.

---

## Leadership

| Role | Name | Background |
|------|------|------------|
| CEO | Demis Hassabis | DeepMind co-founder |
| President | Colin Murdoch | Former GSK |

---

## Alphabet connection

| Aspect | Detail |
|--------|--------|
| Spinout | From DeepMind (2021) |
| Technology | AlphaFold licensed |
| Independence | Separate entity |
| Funding | Alphabet + external |

---

## Competitive advantages

| Advantage | Detail |
|-----------|--------|
| AlphaFold | Best-in-class protein prediction |
| DeepMind talent | World-class AI researchers |
| Alphabet backing | Deep pockets |
| Pharma validation | $3B in deals |

---

## Investment case

**Bull:**
- AlphaFold 3 technology lead
- $3B pharma deal validation
- Alphabet backing
- Demis Hassabis leadership
- First trials 2026

**Bear:**
- Private (no public access)
- Unproven in clinic
- Competition from Recursion, Insilico
- Structure prediction ≠ drug success
- Long timeline to revenue

---

## Quick stats

| Metric | Value |
|--------|-------|
| Status | Private |
| Parent | Alphabet |
| Funding | $600M |
| Platform | AlphaFold 3 |

---

## Related

- [[AI drug discovery]] — concept
- [[Google DeepMind]] — parent technology
- [[Demis Hassabis]] — CEO
- [[Eli Lilly]] — partner
- [[Recursion]] — competitor
- [[Insilico Medicine]] — competitor

---

## Sources

- [TechCrunch: Lilly/[[Novartis]] deals](https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery/)
- [Clinical Trials Arena: Trial prep](https://www.clinicaltrialsarena.com/news/isomorphic-labs-prepares-trials-ai-designed-drugs/)

*Created 2026-01-09*
